Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II)

Abstract: Major membrane lipids were quantified in frontal (Brodmann area 9) and temporal (Brodmann areas 21 and 22) cortices, caudate nucleus, hippocampus, and frontal white matter of 12 cases with Alzheimer's disease (AD) type I (early onset), 21 cases with AD type II (late onset), and 20 age‐matched controls. The concentration of gangliosides—a marker for axodendritic arborization—was reduced to 58–70% of the control concentration in all four gray areas (p < 0.0001) and to 81 % in frontal white matter (p < 0.01) of AD type I cases, whereas it was only significantly reduced in temporal cortex (p < 0.01), hippocampus (p < 0.05), and frontal white matter (p < 0.05) in AD type II cases. The concentration of phospholipids was also significantly reduced (p < 0.01–0.0001) in all four gray areas of AD type I cases but in no area of AD type II cases. The loss of cholesterol was only 50% of the corresponding phospholipid diminution in AD type I. These results suggested a pronounced loss of nerve endings in AD type 1. The characteristic membrane lipid disturbance in AD type II was a loss of myelin lipids. This is the first time a fundamental biochemical difference has been shown between the two major forms of AD.

[1]  D. Selkoe The molecular pathology of Alzheimer's disease , 1991, Neuron.

[2]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Sjogren,et al.  Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. , 1952, Acta psychiatrica et neurologica Scandinavica. Supplementum.

[4]  J. Talan-Hranilović,et al.  Brain gangliosides in Alzheimer's disease. , 1990, Journal fur Hirnforschung.

[5]  M. Roth,et al.  The association of clinical and neurological findings and its bearing on the classification and aetiology of Alzheimer's disease. , 1986, British medical bulletin.

[6]  M. Malone,et al.  Neurochemical changes in white matter. Aged human brain and Alzheimer's disease. , 1985, Archives of neurology.

[7]  K. Schauenstein,et al.  Quantitative immunohistochemistry. , 1980, Acta histochemica. Supplementband.

[8]  K. Blennow,et al.  Confusional symptomatology distinguishes early— and late- onset Alzheimer’s disease , 1990, Aging.

[9]  L. Svennerholm,et al.  A procedure for the quantitative isolation of brain gangliosides. , 1980, Biochimica et biophysica acta.

[10]  J. Kasanin,et al.  CLINICOPATHOLOGIC STUDY OF ALZHEIMER'S DISEASE: RELATIONSHIP TO SENILE CONDITIONS , 1936 .

[11]  E. Masliah,et al.  Alz-50 recognizes a phosphorylated epitope of tau protein , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  E. Masliah,et al.  Quantitative immunohistochemistry of synaptophysin in human neocortex: an alternative method to estimate density of presynaptic terminals in paraffin sections. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  D. Bowen,et al.  Chemical pathology of this organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains. , 1977, Brain : a journal of neurology.

[14]  H. Sjogren Twenty-four cases of Alzheimer's disease; a clinical analysis. , 1950, Acta medica Scandinavica. Supplementum.

[15]  Walter Schubert,et al.  Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites , 1991, Brain Research.

[16]  K. Blennow,et al.  Presence of parieto‐temporal symptomatology distinguishes early and late onset Alzheimer's disease , 1991 .

[17]  R. S. J. Frackowiak,et al.  REGIONAL CEREBRAL OXYGEN SUPPLY AND UTILIZATION IN DEMENTIAA CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN-15 AND POSITRON TOMOGRAPHY A CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN - 15 AND POSITRON TOMOHRAPHY , 1981 .

[18]  K. Jellinger,et al.  Synaptic pathology in alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles , 1992, Neuroscience.

[19]  R. Katzman.,et al.  CHEMICAL STUDIES ON ALZHEIMER'S DISEASE , 1965, Journal of neuropathology and experimental neurology.

[20]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[21]  S. DeKosky,et al.  Aging, senile dementia, and the intralaminar microchemistry of cerebral cortex , 1982, Neurology.

[22]  J. Hawthorne,et al.  Reduced Phosphoinositide Concentrations in Anterior Temporal Cortex of Alzheimer‐Diseased Brains , 1987, Journal of neurochemistry.

[23]  G. Schwarzmann,et al.  A simple and novel method for tritium labeling of gangliosides and other sphingolipids. , 1978, Biochimica et biophysica acta.

[24]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[26]  R. Terry THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMER'S DISEASE , 1963, Journal of neuropathology and experimental neurology.

[27]  B. Tomlinson Plaques, tangles and Alzheimer's disease , 1982, Psychological Medicine.

[28]  H. Wiśniewski,et al.  Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia , 1979, Annals of neurology.

[29]  Stephen W. Scheff,et al.  Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.

[30]  A. Cyrus,et al.  THE QUANTITATIVE ESTIMATION OF GLYCOLIPIDS IN ALZHEIMER'S DISEASE * , 1966, Journal of neurochemistry.

[31]  A. Brun,et al.  A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study , 1986, Annals of neurology.

[32]  P. Greengard,et al.  Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities. , 1992, Trends in pharmacological sciences.

[33]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology , 1987 .

[34]  L. Svennerholm,et al.  Membrane Lipids in the Aging Human Brain , 1991, Journal of neurochemistry.

[35]  W. Meier-Ruge,et al.  ACCELERATED AGEING OR SELECTIVE NEURONAL LOSS AS AN IMPORTANT CAUSE OF DEMENTIA? , 1979, The Lancet.

[36]  D. Bowen,et al.  Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease. , 1986, British medical bulletin.

[37]  D. Bowen,et al.  Molecular changes in senile dementia. , 1973, Brain : a journal of neurology.

[38]  P. Hietala,et al.  Quantitative Estimation of Sialic Acids. III. An Anion Exchange Resin Method. , 1958 .

[39]  L. Svennerholm,et al.  CHANGES IN FATTY ACID COMPOSITION OF HUMAN BRAIN MYELIN LIPIDS DURING MATURATION 1 , 1978, Journal of neurochemistry.

[40]  J. Talan-Hranilović,et al.  Cortical distribution of gangliosides in Alzheimer's disease , 1992, Neurochemistry International.

[41]  David A. Drachman,et al.  Synaptic loss in Alzheimer's disease and other dementias , 1989, Neurology.

[42]  B. Vogt,et al.  Brain gangliosides in dementia of the Alzheimer type. , 1989, Archives of neurology.

[43]  D. Mann,et al.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease , 1987, Journal of the Neurological Sciences.

[44]  T Jones,et al.  Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. , 1981, Brain : a journal of neurology.

[45]  J. Månsson,et al.  Human brain gangliosides: developmental changes from early fetal stage to advanced age. , 1989, Biochimica et biophysica acta.

[46]  L. Gustafson,et al.  Differential diagnosis of presenile dementia on clinical grounds , 1982, Acta psychiatrica Scandinavica.